Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dl at baseline (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement: \r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dl at baseline (may receive packed red blood cell [PRBC] transfusions)
* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8 g/dL
Platelet count >= 100,000/uL (transfusion independent)
Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 90 days prior to step 1 registration
Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvement
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\r\n* Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 75,000/ul (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
Platelet count >= 75,000/uL (transfusion independent for >= 7 days)
Platelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to enrollment) for subjects without bone marrow involvement
Platelet count >= 75 × 10^9/L or >= 50× 10^9/L if there is lymphoma involvement in the bone marrow, independent of platelet transfusion
Screening platelet count should be independent of platelet transfusions for at least 2 weeks.
Platelet count >= 100,000/uL (transfusion independent)
Platelet count ? 75,000/uL (transfusion independent)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 75 x 10^9/L (transfusion independent for > 7 days)
Platelet count >= 75,000 and transfusion independent
Platelet count of at least 100,000/L (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)
Platelet count >= 75,000/uL (transfusion independent)
Platelet count: >= 50,000 (transfusion independent; >= 7 days from last transfusion)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count ? 100,000/mm3 (transfusion independent defined as no platelet transfusion within 7 days and recovery from nadir)
Platelet count >= 100,000/mm^3 (transfusion independent defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) within 14 days of registration
Platelet count >= 100,000/uL (transfusion independent)
Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization
Platelet count >= 100,000/ mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count of >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)
PART 2 GROUP 1 INCLUSION CRITERIA: Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
PART 2 GROUP 3 INCLUSION CRITERIA: Platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/uL (transfusion independent)
Platelet count of >= 100 k/mL independent of transfusion and/or growth factors within 3 months prior to randomization
Platelets >= 100,000/mcL (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)
Platelets >= 75,000/mcl (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
Platelets >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within 7 days\r\nprior to laboratory sample)
Platelet count >= 100,000 x 10^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization
Platelet count >= 100,000/uL independent of transfusion and or growth factors within 3 months prior to enrollment
Platelet count (transfusion independent) >= 75,000/mm^3
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 7 days prior to enrollment \r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 50,000/ul (transfusion independent)
For subjects with solid tumors without known bone marrow involvement: platelet count >= 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count > 100,000/mm^3; independent of transfusion
Platelet count 50,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment. Exception: Patients that are platelet dependent due to previous extensive treatment- e.g. - MIBG therapy).
Screening platelet count should be independent of platelet transfusions for at least 1 week
Platelet count >= 100,000/uL (transfusion independent)
Platelet count ?100 × 10^9/L (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to study drug administration)
Platelet count >= 50,000 mm^3; platelet count should be independent of transfusions for at least 14 days for eligibility
Platelet count >= 100,000/uL (transfusion independent)
Platelet count: >= 50,000/ul, transfusion independent (no platelet transfusions within 1 week)
For subjects with solid tumors without known bone marrow involvement: \r\n*Platelet count ? 75,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Obtained within 28 days prior to registration: Platelets > 100,000 cells/mm^3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)
Platelet count > 100,000/mm^3. Patients who have bone marrow infiltration by MCL are eligible if their platelet level is >= 50,000 /mm^3 independent of platelet transfusions.
For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Within 7 days prior to study registration: Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelets >= 100,000/mm^3 (transfusion independent (except for patients with marrow involvement by disease where there is no blood count requirement, except for platelet count which must be >= 25,000 prior to enrollment (can be achieved with transfusion)
Platelet count >= 50,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); in NB patients with known bone marrow involvement relaxed platelet count eligibility requirement should be used: a platelet count of >= 20,000/mm that can be maintained with =< 1 platelet transfusion per week
Platelet count >= 100,000/uL (transfusion independent)
Platelet count: >= 50,000/mm^3, transfusion independent (no platelet transfusions within 1 week)
Platelet count > 100,000/uL (transfusion independent)
Platelet count >= 75,000/uL (transfusion independent)\r\n* If the ANC and/or platelet count are not adequate, but due to bone marrow metastatic disease, these criteria will be waived
For patients with solid tumors without bone marrow involvement: platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
For patients with solid tumors and known bone marrow metastatic disease: platelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
For patients with solid tumors without known bone marrow involvement: platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/uL (transfusion independent)
For patients with solid tumors or ALCL without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/uL (transfusion independent)
Platelet transfusion independent for at least 4 weeks prior to enrollment
Platelet count >= 75,000/uL (transfusion independent)
Platelet count >= 100,000/mm^3 (transfusion independent)
Platelet count > 30,000 K/uL independent of transfusion support
Platelets >= 100,000 cells/mm^3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)
Within 28 days prior to signing informed consent: Platelet counts >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement with lymphoma, independent of transfusion support in either situation
Platelets >= 100,000/mcL (transfusion independent, defined as not receiving platelet transfusions within a 7-day period prior to enrollment)
Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) and
Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 75,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Platelet count >= 100,000/uL (transfusion independent)
Platelet count >= 100,00 mm^3 independent of transfusion support
Platelet count < 50,000 cells/mm^3 (50 x 10^9/L) independent of transfusion support
Platelets: >= 100,000/mm^3 (transfusion independent defined as not receiving platelet transfusions within 7 days prior to registration)
Platelet count >= 75,000/uL (transfusion independent)
Platelet count >= 75,000/uL for patients with solid tumors without bone marrow involvement (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment); platelet count >= 25,000/uL for patients with known bone metastatic disease (transfusions are permitted to reach the platelet criteria)
Platelet count >= 75,000/ mm^3 (transfusion independent for > 7 days)
Platelet count >= 75,000/uL (transfusion independent)
Screening platelet count should be independent of platelet transfusions for at least 2 weeks
Screening platelet count >= 50 x 10^9/L independent of platelet transfusions for at least 2 weeks
Platelet count: 100,000/ul and transfusion independent (no platelet transfusions within 7 days of blood draw documenting eligibility)
Platelet count > 100,000/uL (transfusion independent)
Platelet count >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement independent of transfusion support in either situation
Platelet count >= 100,000/mm3 independent of transfusion support OR >= 50,000/mm3 independent of transfusion\r\nsupport if bone marrow involvement
Transfusion independent
Platelet count >= 25,000 cells/mm^3 (25 x 10^9/L) independent of transfusion within 7 days of screening
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement:\r\n* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment
Platelet count >= 100,000/uL (transfusion independent)
Platelet count >= 40,000 cells/mm^3 (40 x 10^9/L) independent of transfusion within 7 days of screening, unless they have significant bone marrow involvement of their malignancy confirmed on biopsy
Platelet count >= 100,000/mm^3 (transfusion independent)
